Introduction: Ocular surface disease (OSD) is a major cause of ophthalmological consultation. Within this group, glaucoma patients constitute an important percentage due to the nature of their chronic topical treatment. Advances in the understanding of ocular surface pathology on both a cellular and molecular level, and the interaction to the toxic nature of some topical medication solution compounds, are stimulating the development of better alternatives in topical treatment.
Materials and Methods: Extensive review of available literature and current research on topical ophthalmological treatments in both OSD and glaucoma was performed. Emphasis was made on inflammatory modulators of the ocular surface and pathological changes associated with the use of preservatives in solutions, in particular benzalkonium chloride (BAK). Independent research is been also performed by the authors, using a rubbing-induced reflex tears collecting method with capillary tubes. Cytokines in tear samples were subsequently analysed with the multi-Plex System (Luminex®R-200). The 12 cytokines analysed using this method are the interleukins (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, the tumour necrosis factor alpha (TNFα), the vascular endothelial growth factor (VEGF), the granulocyte-macrophage-colony stimulating factor (GM-CSF) and the interferon gamma (IFg).
Results: Our unpublished, preliminary results trend to show higher values in IL-5 and IL-6 in glaucoma patients than in normal controls.
Also, higher values in IL-2, IL-5 and IL-12 in DES patients were found versus normal controls.
Conclusions: Inflammation is an important element in OSD and strong association seems to exist between this and the use of BAK
preservative. New kinds of preservative molecules, as well as single-dose eye drops and sophisticated dispensing bottle mechanisms are
currently available on the market in order to avoid the secondary effects of this topical treatments, increasing patient compliance and
adherence to chronic topical glaucoma treatment.
Ocular surface, glaucoma, benzalkonium chloride, preservatives, conjunctiva, cornea, inflammation
The authors have no conflicts of interest to declare.
Javier Benitez-del-Castillo, Plaza Monti, 7 Bajo, 11403 Jerez (Cadiz), Spain. E: email@example.com
Share this Article
Related Content In Ocular Surface Disease
Novel Molecule Lotilaner Could Potentially Offer Relief to Long-suffering Demodex Blepharitis Patients
touchREVIEWS in Ophthalmology 2022;16(1):2–5 DOI: https://doi.org/10.17925/USOR.2022.16.1.2
Demodex blepharitis is a highly prevalent lid margin disease that is commonly missed or misdiagnosed by eye care professionals. The disease is caused by an infestation of Demodex mites – tiny parasites that live in the eyelash follicles and feed on oily sebum. When present in small numbers, the effects of these mites are subclinical and are likely […]
The Impact of Continuous Positive Airway Pressure Use on Dry Eye Disease
touchREVIEWS in Ophthalmology. 2021;16(1):40–1 DOI: https://doi.org/10.17925/USOR.2022.16.1.40
The prevalence of both dry eye disease and sleep apnoea has steadily increased in the USA.1 Importantly, new research reveals the need for multispecialty collaboration based on evidence that patients may be at risk for eye irritation secondary to airflow from mask leakage or retrograde nasolacrimal air escape.2 Sleep apnoea and ocular disorders Sleep apnoea is […]
KPI-121 0.25%: A New Option for the Treatment of Dry Eye Disease
touchREVIEWS in Ophthalmology. 2021;15(2):58-62 DOI: https://doi.org/10.17925/USOR.2021.15.2.58
Dry eye disease (DED) is an inflammatory condition of the cornea and conjunctiva that is characterized by tear-film instability and increased tear osmolarity.1–3 While DED is traditionally viewed as a chronic condition, many patients experience episodic exacerbations of the disease, also referred to as flares or episodic dry eye.1 Until recently, the need for an effective treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!